Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Rev Allergy Immunol. 2008 Feb;34(1):74-9. doi: 10.1007/s12016-008-8074-1.

Rituximab: beyond simple B cell depletion.

Author information

1
Division of Clinical Immunology and Allergy, Bnai Zion Medical Center, Technion, Rappaport Faculty of Medicine, Haifa, P.O.B. 4940, Israel.

Abstract

Rituximab, a chimeric anti-CD20 monoclonal antibody, has a proven track record for over a decade in the treatment of lymphomas, where it has been used to eradicate malignant lymphocytes. In appreciation of the putative role of B cells, especially with respect to autoantibody production, in the pathogenesis of autoimmune diseases, successful trials of B-cell depletion therapy in RA, SLE, and other autoimmune diseases have been carried out. In these trials, clinical benefit has generally correlated with the extent and duration of B-cell depletion, but at times imperfectly, and autoantibody reduction only selectively. Additional mechanisms whereby rituximab may assert its clinical benefit in autoimmune diseases have been examined including a look at B-cell functions as T-cell modulator and antigen-presenting cell, T-regulatory cell behavior, NK cell activity, and macrophage activities in immune inflammation. The available data on rituximab's action in autoimmune diseases is reviewed.

PMID:
18240027
DOI:
10.1007/s12016-008-8074-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center